Skip to main content
. 2023 May 15;45(5):4331–4343. doi: 10.3390/cimb45050275

Figure 2.

Figure 2

Efficacy of Th17-targeted therapy in SLE based on available evidence. AIHA—autoimmune hemolytic anemia, CNS—central nervous system, CR—case report, GUS—guselkumab, IL—interleukin, LN—lupus nephritis, NPSLE—neuropsychiatric systemic lupus erythematosus, RCT—randomized clinical trial, RIS—risankizumab, SEC—secukinumab, SLE—systemic lupus erythematosus, UST—ustekinumab.